rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In the real-life setting, activity and safety of BRAFi + MEKi in V600E BRAFm NSCLC are comparable to those observed in prospective clinical trials; the combination of BRAFi + MEKi is superior to monotherapy with a BRAFi.
|
31060855 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The US Food and Drug Administration approved a liquid biopsy test for EGFR-activating mutations in patients with non-small-cell lung cancer as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in non-small-cell lung cancer. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30883505 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Among the 53 NSCLC samples, only 5 (9.3%) cases harbored BRAF V600E mutation, 80% were of adenocarcinoma type, and the rest (20%) was of squamous cell carcinoma.
|
31781475 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Here, in this review, we outline the preclinical and clinical data for BRAF and MEK inhibitor combination treatment for NSCLC patients with BRAF V600E mutation.
|
29595366 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Dabrafenib Plus Trametinib for BRAF V600E-Mutant Non-small Cell Lung Cancer: A Patient Case Report.
|
31250402 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Molecular alterations that predict response to treatment (eg, EGFR mutations, ALK rearrangements, ROS1 rearrangements, and BRAF V600E mutations) are present in approximately 30% of patients with non-small cell lung cancer.
|
31454018 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The test was shown to accurately and reliably select patients with NSCLC with the <i>BRAF</i> V600E mutation for whom treatment with dabrafenib and trametinib is the optimal treatment.
|
29438093 |
2018 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The US FDA approved a liquid biopsy test for EGFR activating mutations in patients with non-small cell lung cancer (NSCLC) as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in NSCLC. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30335711 |
2018 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Due to the rarity of BRAF V600E mutation, no randomized study has compared the combination targeted therapy dabrafenib + trametinib with other second-line treatments for advanced or metastatic non-small-cell lung cancer (NSCLC).
|
29949047 |
2018 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In the present review, we propose an overview of the available evidence about BRAF in NSCLC mutations (V600E and non-V600E), from biological significance to emerging clinical implications of BRAF mutations detection.
|
29729495 |
2018 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
BRAF inhibition has demonstrated anti-tumor activity in patients with BRAF V600E mutant NSCLC.
|
30019008 |
2018 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
This paper summarizes the clinical evidence that lead to the recent approval of the combination of dabrafenib and trametinib to treat patients with advanced NSCLC who harbor a BRAF V600E mutation.
|
29662327 |
2018 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
ICPi have favorable activity both in BRAF V600E and BRAF non-V600E mutant NSCLC.
|
29723688 |
2018 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The vast majority of the BRAF V600E mutations were found in cerebral metastases of malignant melanomas and carcinomas (29/135, 22 %), with false-positive staining found in four breast cancer cases and two non-small-cell lung carcinoma (NSCLC) samples.
|
27350555 |
2016 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Dabrafenib showed clinical activity in BRAF(V600E)-positive NSCLC.
|
27080216 |
2016 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Dabrafenib plus trametinib could represent a new targeted therapy with robust antitumour activity and a manageable safety profile in patients with BRAF(V600E)-mutant NSCLC.
|
27283860 |
2016 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Oncogenic BRAF V600E (BRAF(V600E)) substitutions are observed primarily in melanoma, colon cancer, and non-small cell lung cancer, but have been identified in multiple tumor types.
|
27048246 |
2016 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Among 2690 patients with genotyped NSCLC during the study period, BRAF mutations were identified in 80 (3%) cases, consisting of V600E substitution in 42 (53%) cases; non-V600E mutation were observed in 38 (48%) cases.
|
26711930 |
2016 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines.
|
27196768 |
2016 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Treatment of V600E BRAF-mutated NSCLC with BRAF inhibitor monotherapy demonstrated encouraging antitumor activity.
|
26301799 |
2015 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In a recent phase II study for patients with BRAF-V600E non-small cell lung cancer</span> (NSCLC), BRAF V600E inhibitor demonstrated evidence of activity, but 30% of this selected group progressed while on treatment, suggesting a need for developing alternative strategies.
|
25706985 |
2015 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Several retrospective studies on BRAF mutations in patients with NSCLC found that the majority of these mutations occur in adenocarcinomas and are V600E mutations.
|
26066373 |
2015 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
BRAF(V600E) cells with EGFR-driven resistance are characterized by hyperphosphorylated protein kinase AKT, a biomarker we validated in BRAF inhibitor-resistant NSCLC clinical specimens.
|
24550319 |
2014 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Results of early-phase clinical trials and case reports demonstrate responses in V600E-mutant non-small-cell lung cancer, thyroid cancer, and hairy cell leukemia.
|
24955706 |
2014 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
NSCLC routinely tested for EGFR-mutations at Oslo University Hospital in the period February 2011-July 2013 were tested for V600E/K BRAF-mutations using a PCR-based method.
|
24552757 |
2014 |